Creative Planning’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34.9M Buy
436,167
+26,410
+6% +$2.18M 0.02% 282
2025
Q4
$34.9M Buy
409,757
+3,717
+0.9% +$305K 0.03% 260
2025
Q3
$31.6M Buy
406,040
+16,631
+4% +$1.3M 0.02% 265
2025
Q2
$30.5M Buy
389,409
+15,336
+4% +$1.14M 0.03% 247
2025
Q1
$27.1M Buy
374,073
+9,843
+3% +$705K 0.03% 257
2024
Q4
$27M Sell
364,230
-20,399
-5% -$1.43M 0.03% 236
2024
Q3
$25.4M Sell
384,629
-4,889
-1% -$355K 0.03% 238
2024
Q2
$36M Buy
389,518
+867
+0.2% +$76.8K 0.04% 178
2024
Q1
$37.1M Buy
388,651
+177,216
+84% +$14.9M 0.04% 170
2023
Q4
$16.1M Buy
211,435
+45,794
+28% +$3.19M 0.03% 284
2023
Q3
$11.5M Sell
165,641
-5,279
-3% -$424K 0.02% 328
2023
Q2
$16.1M Buy
170,920
+9,052
+6% +$787K 0.02% 260
2023
Q1
$13.4M Buy
161,868
+4,848
+3% +$381K 0.02% 281
2022
Q4
$11.7M Buy
157,020
+8,530
+6% +$657K 0.02% 308
2022
Q3
$12.3M Buy
148,490
+8,448
+6% +$813K 0.02% 266
2022
Q2
$13.3M Buy
140,042
+2,433
+2% +$252K 0.02% 270
2022
Q1
$16.2M Buy
137,609
+16,689
+14% +$1.87M 0.03% 240
2021
Q4
$15.7M Buy
120,920
+3,758
+3% +$438K 0.03% 214
2021
Q3
$13.3M Sell
117,162
-1,366
-1% -$156K 0.02% 224
2021
Q2
$12.3M Sell
118,528
-2,125
-2% -$200K 0.02% 235
2021
Q1
$10.1M Sell
120,653
-1,667
-1% -$141K 0.02% 273
2020
Q4
$11.2M Buy
122,320
+6,648
+6% +$551K 0.02% 238
2020
Q3
$9.23M Buy
115,672
+6,599
+6% +$515K 0.02% 223
2020
Q2
$7.54M Buy
109,073
+1,106
+1% +$78.6K 0.02% 227
2020
Q1
$6.79M Sell
107,967
-2,457
-2% -$177K 0.02% 216
2019
Q4
$8.59M Buy
110,424
+7,878
+8% +$615K 0.03% 217
2019
Q3
$7.52M Buy
102,546
+6,102
+6% +$429K 0.02% 226
2019
Q2
$5.94M Sell
96,444
-4,581
-5% -$277K 0.02% 256
2019
Q1
$6.44M Sell
101,025
-2,982
-3% -$170K 0.02% 227
2018
Q4
$5.31M Buy
104,007
+33
+0% +$1.67K 0.02% 235
2018
Q3
$6.03M Sell
103,974
-141
-0.1% -$6.9K 0.02% 240
2018
Q2
$5.05M Buy
104,115
+2,547
+3% +$119K 0.02% 253
2018
Q1
$4.72M Buy
101,568
+1,506
+2% +$65.4K 0.02% 256
2017
Q4
$3.76M Buy
100,062
+1,719
+2% +$63.1K 0.02% 302
2017
Q3
$3.58M Sell
98,343
-1,743
-2% -$66.5K 0.02% 305
2017
Q2
$3.94M Sell
100,086
-33,885
-25% -$1.24M 0.02% 270
2017
Q1
$4.2M Sell
133,971
-3
-0% -$94 0.02% 238
2016
Q4
$4.18M Buy
133,974
+17,031
+15% +$552K 0.03% 235
2016
Q3
$4.7M Buy
116,943
+9,999
+9% +$377K 0.03% 215
2016
Q2
$3.56M Sell
106,944
-5,874
-5% -$201K 0.03% 217
2016
Q1
$3.32M Buy
112,818
+43,818
+64% +$1.21M 0.03% 215
2015
Q4
$1.82M Sell
69,000
-2,400
-3% -$62.3K 0.01% 335
2015
Q3
$1.69M Sell
71,400
-9,876
-12% -$238K 0.01% 333
2015
Q2
$1.93M Buy
81,276
+22,122
+37% +$499K 0.02% 297
2015
Q1
$1.41M Sell
59,154
-396
-0.7% -$8.88K 0.01% 358
2014
Q4
$1.26M Buy
59,550
+29,238
+96% +$587K 0.01% 381
2014
Q3
$516K Buy
30,312
+546
+2% +$8.62K 0.01% 642
2014
Q2
$426K Sell
29,766
-408
-1% -$5.53K 0.01% 704
2014
Q1
$373K Sell
30,174
-810
-3% -$9.35K 0.01% 739
2013
Q4
$340K Sell
30,984
-8,898
-22% -$100K 0.01% 640
2013
Q3
$463K Buy
39,882
+15,516
+64% +$182K 0.01% 470
2013
Q2
$273K Buy
+24,366
New +$288K 0.01% 583

Other funds holding EW

Creative Planning's EW Position: Q1 2026 in Review

Creative Planning increased its Edwards Lifesciences (EW) stake by 6.4% in Q1 2026, buying an estimated $2.18M and bringing the position to 436,167 shares worth $34.9M. The position accounts for 0.02% of the portfolio, ranked #282.

Creative Planning first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $37.1M in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Creative Planning held 436,167 shares of Edwards Lifesciences worth $34.9M as of Q1 2026.
  • Creative Planning bought 26,410 Edwards Lifesciences shares in Q1 2026, an estimated $2.18M.
  • Edwards Lifesciences made up 0.02% of Creative Planning's portfolio in Q1 2026, its #282 holding.
  • Creative Planning first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Creative Planning's Edwards Lifesciences position peaked at $37.1M in Q1 2024.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.